ShortBusters Club's Dirks Issues Buy Recommendation on

Hemispherx - Projects $1.60 EPS for Just 1% Global MarketPenetration for CFS New York (ots-PRNewswire) - Ray Dirks, founder of theShortBusters Club, has issued a buy recommendation on HemispherxBiopharma, Inc. (Amex: HEB), based on important progress in theCompany's development of a new class of drugs for the treatmentof chronic viral disorders and disorders of the immune system. Mr. Dirks, whose comments appear in the January/February issueof Equities magazine that was just released, states thatAmpligen, which is in Phase III clinical testing for thetreatment of Chronic Fatigue Syndrome (CFS), would have a seven-year legal monopoly in the U.S. if approved because of the OrphanDrug status it has been accorded by the FDA and has anapplication pending with the FDA for fast track approval. TheCompany has already submitted an application for marketing thedrug in the European Union. In the article, Mr. Dirks states that his health-care industryanalysts project that Hemispherx would realize pre-tax earningsof approximately $40 million, or $1.60 net earnings per share, bypenetrating just 1% of the potential global market for CFS. Overall, according to the article, Hemispherx could be withintwo years of marketing its lead drug for the treatment of CFS andlonger-term has the potential for application in the treatment ofadditional chronic viral diseases, including HIV and Hepatitis B. ShortBusters Club, founded in 1990 by Ray Dirks, disseminatesresearch on fundamental strengths and growth prospects ofcompanies whose stocks are under attack by abusive short sellers.Ray Dirks is with Security Capital Trading, a member of theNational Association of Securities Dealers, CRD number 35909.ots Original Text Service: ShortBusters Club Internet:http://www.newsaktuell.de Contact: Ray Dirks of ShortBustersClub (USA) 212-339-2001.

Upozorňujeme odběratele, že materiály označené značkouPROTEXT nejsou součástí zpravodajského servisu ČTK a nelze jepublikovat pod její značkou. Jde o komerční sdělení zadavatele,který je ve zprávě označen a který za něj nese plnou odpovědnost.

PROTEXT